SHANGHAI – Hutchison China Meditech Ltd. (Chi-Med), of Shanghai, presented at the recent American Society of Clinical Oncology meeting in Chicago full phase III data for fruquintinib, an oral VEGF inhibitor, for third-line colorectal cancer (CRC). The firm is now in the process of filing an NDA in China where there is no approved drug for third-line CRC. Chinese patients who have failed two prior chemo treatments are a step closer to a treatment that is less toxic and can add 2.7 months over current standard of care.